Allergy Therapeutics Initiates Second Year of Phase III Pediatric Grass Allergy Trial
核心洞察
Allergy Therapeutics (搜索) has commenced patient screening for the second year of its Phase III G308 trial evaluating Grass MATA MPL in pediatric patients with grass allergies.
The study represents the first subcutaneous allergen-specific immunotherapy trial designed to assess both short and long-term outcomes in children.
The trial design minimizes placebo exposure with only 8-13% of patients receiving long-term placebo treatment, compared to the standard 50% probability.
Allergy Therapeutics (搜索) has begun patient screening for the second year of its Phase III G308 trial, marking a significant milestone in pediatric allergy treatment development. The trial evaluates the long-term efficacy and safety of Grass MATA MPL, a subcutaneous immunotherapy for children with grass allergies, representing the first study of its kind designed to assess both short and long-term outcomes in pediatric subjects.
Trial Design and Timeline
The screening and randomization period is planned for completion by early Q1 2026, allowing all scheduled injections of Grass MATA MPL to be administered before the 2026 grass pollen season begins. The second year aims to achieve similar enrollment numbers to the first year, which successfully randomized 190 participants.
Short-term safety data from the first year is expected to be announced in Q4 2025, with full analysis of short-term safety and efficacy results scheduled for Q4 2026. Patients selected for the long-term extension will progress to three additional years of active treatment or placebo, followed by two years of treatment-free follow-up before final evaluation of long-term primary efficacy and safety.
Innovative Study Design
The G308 study incorporates a patient-centric design that significantly reduces placebo exposure. Only a minority of patients (approximately 8-13% probability) will receive long-term placebo treatment, representing a substantial improvement over the European Medicines Agency standard design, which typically involves 50% probability of placebo assignment. This approach enables the majority of pediatric patients to receive long-term active treatment.
Treatment Mechanism
Grass MATA MPL contains an extract of 13 grass pollens modified with glutaraldehyde to form allergoids, which reduces reactivity with immunoglobulin E (IgE (搜索)) antibodies while maintaining important immunological properties such as T-cell reactivity. The allergoid is adsorbed to microcrystalline tyrosine as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL) is included as an adjuvant to enhance the immunogenic effect and promote the switch from an allergen-specific helper T-cell Type 2 (Th2 (搜索)) to helper T-cell Type 1 (Th1 (搜索)) immune response.
Clinical Development Investment
Manuel Llobet, CEO of Allergy Therapeutics (搜索), emphasized the company's commitment to addressing unmet needs in pediatric grass allergy treatment. "Overall we have invested over $100M in clinical development in grass allergy to date and combined with our successful adult trials, this long-term trial will help us in our aim to provide children affected by grass allergies with an alternative treatment journey that is less burdensome compared to taking tablets daily," Llobet stated.
The substantial investment reflects the company's broader strategy to develop comprehensive allergy immunotherapies across both adult and pediatric populations, positioning Grass MATA MPL as a potential alternative to daily oral medications for children with grass allergies.